Neuronetics to Present at the Canaccord Genuity 41st Annual Growth Conference

Rhea-AI Summary

Neuronetics, a commercial-stage medical technology company focused on improving the quality of life for psychiatric disorder patients, announced its participation in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021. CEO Keith Sullivan and CFO Steve Furlong will present at 9:30 am ET. The presentation will be available via live audio webcast on the company’s investor relations page, with a replay accessible for 90 days. Neuronetics’ flagship product, NeuroStar, is a FDA-cleared therapy for major depressive disorder.

MALVERN, Pa., July 29, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer, will participate in the Canaccord Genuity 41^st Annual Growth Conference on Thursday, August 12, 2021. The Company is scheduled to present at the conference at 9:30 am Eastern Time the same day via webcast.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.neuronetics.com. A replay of the webcast will be archived on the website for approximately 90 days.

About Neuronetics
Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Our first commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.

Investor Contact:
Mike Vallie or Mark Klausner
Westwicke Partners
443-213-0499
ir@neuronetics.com

Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com

FAQ

What is Neuronetics' participation in the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021?

Neuronetics will present at the conference at 9:30 am ET, featuring CEO Keith Sullivan and CFO Steve Furlong.

How can I access the Neuronetics presentation from the Canaccord Genuity conference?

The presentation will be available via a live audio webcast on Neuronetics' investor relations page.

What is NeuroStar, Neuronetics' main product?

NeuroStar is a FDA-approved non-invasive treatment for major depressive disorder, utilizing transcranial magnetic stimulation.

How long will the Neuronetics conference presentation replay be available?

The replay of the conference presentation will be available for approximately 90 days.

What is the stock symbol for Neuronetics?

The stock symbol for Neuronetics is STIM.